• Company Type For Profit
  • Contact Email info@ganymed.ag
  • Phone Number 49 6131 1440 100

Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched

tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.

Lists Featuring This Company

Closed Europe, Middle East, and Africa (EMEA) Biotechnology Companies
830 Number of Organizations • $7.4B Total Funding Amount • 1,199 Number of Investors
Acquired Rheinland-Pfalz Companies
192 Number of Organizations • $295.4M Total Funding Amount • 43 Number of Investors
MIG Capital Portfolio Companies
36 Number of Organizations • $4.5B Total Funding Amount • 279 Number of Investors
Closed Europe Companies (Top 10K)
9,451 Number of Organizations • $48.5B Total Funding Amount • 10,245 Number of Investors
Ganymed Pharmaceuticals was acquired by Astellas Pharma for $1.4B on Oct 28, 2016.

Frequently Asked Questions

Where is Ganymed Pharmaceuticals's headquarters? Ganymed Pharmaceuticals is located in Mainz, Rheinland-Pfalz, Germany.Who invested in Ganymed Pharmaceuticals? Ganymed Pharmaceuticals has 8 investors including Future Capital and MIG Capital.How much funding has Ganymed Pharmaceuticals raised to date? Ganymed Pharmaceuticals has raised .When was the last funding round for Ganymed Pharmaceuticals? Ganymed Pharmaceuticals closed its last funding round on Nov 18, 2013 from a Series E round.